💊 Drugs A-Z 🧬 Targets 🛠 Tools 📚 Guides
All Drugs Drug Classes Therapeutic Areas Side Effects
Guides Glossary Timeline
Comparisons Drug Journeys Drug Families
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Methylprednisolone

CHEMBL650 Phase 4 Approved Small molecule
Half-Life
18-36 hours
Bioavailability
—
Protein Binding
—
Molecular Weight
374.5 g/mol
LogP
1.9
Phase
4

A corticosteroid used to treat a wide range of inflammatory and autoimmune conditions, including allergic reactions, asthma flares, rheumatoid arthritis, and multiple sclerosis relapses. It is available in oral, injectable, and topical forms.

Molecular Weight

374.4710 g/mol

LogP

1.90

TPSA

94.80 Ų

Lipinski RO5

Pass

Therapeutic Areas

Age-Related Macular Degeneration Alzheimer's Disease Asthma Atopic Dermatitis Bipolar Disorder Bladder Cancer Breast Cancer Cardiovascular Disease Chronic Kidney Disease Chronic Obstructive Pulmonary Disease Chronic Pain Colorectal Cancer Epilepsy Gastroesophageal Reflux Disease Generalized Anxiety Disorder Glaucoma Gout Heart Failure HIV/AIDS Hypertension Infectious Disease Inflammatory Bowel Disease Insomnia Leukemia Lymphoma Melanoma Migraine Multiple Sclerosis Non-Alcoholic Fatty Liver Disease Non-Small Cell Lung Cancer Obesity Osteoporosis Ovarian Cancer Pain Management Pancreatic Cancer Parkinson's Disease Prostate Cancer Psoriasis Respiratory Disease Rheumatoid Arthritis Schizophrenia Stroke Systemic Lupus Erythematosus Thyroid Cancer Tuberculosis Type 2 Diabetes

Drug Classes

H — H - Systemic Hormonal Preparations, Excluding Sex Hormones and Insulins

Mechanism of Action

Intermediate-acting synthetic glucocorticoid.

Pharmacokinetics (PK)

Half-Life 18-36 hours

Pharmacodynamics (PD)

Mechanism

Intermediate-acting synthetic glucocorticoid.

2D Structure

SVG PNG

Cite this structure


                        

                            
                            
                        

                    

                


                
                

                    

                    

                        
Embed this structure

                        

                        

                            
                            
                        

                    

                

                

                
                

                    
SMILES

                    
C[C@H]1C[C@@H]2[C@H]([C@@H](O)C[C@@]3(C)[C@H]2CC[C@]3(O)C(=O)CO)[C@@]2(C)C=CC(=O)C=C12

                

                

                
                

                    
InChI

                    
InChI=1S/C22H30O5/c1-12-8-14-15-5-7-22(27,18(26)11-23)21(15,3)10-17(25)19(14)20(2)6-4-13(24)9-16(12)20/h4,6,9,12,14-15,17,19,23,25,27H,5,7-8,10-11H2,1-3H3/t12-,14-,15-,17-,19+,20-,21-,22-/m0/s1

                

                

                

                    
                    

                        
Molecular Formula

                        
C22H30O5

                    

                    
                    

                        
HBD / HBA

                        
3 / 5

                    

                    
                    

                        
Rotatable Bonds

                        
2

                    

                    
                    
                    

                        
Heavy Atoms

                        
27

                    

                    
                

            


            
            

                
                

                    
                    

                        

                            PPARG (Peroxisome Proliferator-Activated Receptor Gamma)
                            Agonist
                        

                        
                        Primary Target
                        
                    

                    
                

                
            


            
            

                
                

                    
                    
                        

                            

  
  Moderate


                            
                                Methylprednisolone + Cyclosporine
                            
                        

                        
                        
Methylprednisolone inhibits CYP3A4-mediated cyclosporine metabolism, raising cyclosporine levels; conversely, cyclosporine may increase methylprednisolone exposure — a bidirectional pharmacokinetic interaction.

                        
                    
                    
                    
                        

                            

  
  Moderate


                            
                                Methylprednisolone + Diltiazem
                            
                        

                        
                        
Diltiazem inhibits CYP3A4-mediated methylprednisolone metabolism, increasing methylprednisolone exposure and the risk of steroid side effects including immunosuppression, hyperglycaemia, and hypertension.

                        
                    
                    
                    
                        

                            

  
  Moderate


                            
                                Methylprednisolone + Fluconazole
                            
                        

                        
                        
Fluconazole inhibits CYP3A4-mediated metabolism of methylprednisolone, increasing its plasma levels and prolonging corticosteroid effects, raising the risk of Cushingoid features.

                        
                    
                    
                

                
            


            
            

                
                


    
    
        
    
    
    
No side effects recorded

    
    
Side effect data is not yet available for this drug.

    



                
            


            
            
            

                
Frequently Asked Questions

                

                    
                    

                        
                        

                            
A corticosteroid used to treat a wide range of inflammatory and autoimmune conditions, including allergic reactions, asthma flares, rheumatoid arthritis, and multiple sclerosis relapses. It is available in oral, injectable, and topical forms.

                        

                    

                    

                    

                    
                    

                        
                        

                            
Intermediate-acting synthetic glucocorticoid.

                        

                    

                    

                    
                    

                        
                        

                            
Key pharmacokinetic parameters for Methylprednisolone: Half-life: 18-36 hours.

                        

                    

                    

                    

                        
                        

                            
Yes, Methylprednisolone is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

                        

                    

                

            

            

            
            

            
            
            

                
Related Drugs


                
                

                    
Same Drug Class

                    

                        
                        
                            Dexamethasone
                            Small molecule
                        
                        
                        
                            Levothyroxine
                            Small molecule
                        
                        
                        
                            Prednisone
                            Small molecule
                        
                        
                    

                

                

                
                
                
            

            

            
            
{# References & Data Sources section for drug detail pages.
   Renders standard pharmacological database links plus the drug's data_sources field. #}


    
References & Data Sources

    
    
        
        
  • 
            
            
                ChEMBL — European Bioinformatics Institute (EBI).
                CHEMBL650.
                Open-access bioactivity database.
            
        
    • 
        
        
        
  • 
            
            
                PubChem — National Center for Biotechnology Information (NCBI).
                CID 6741.
                Chemical information database.
            
        
    • 
        
        
        
        
    

    
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.




        


        
        
    


    



    
Medical Disclaimer

    

        This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
    

    

        Data sources:
        ChEMBL,
        PubChem,
        DailyMed.